Abstract | BACKGROUND: MATERIALS AND METHODS: This was an open-label, phase Ib study assessing the safety, tolerability, and preliminary efficacy of atezolizumab plustazemetostat in patients with R/R DLBCL. Atezolizumab (1200 mg) was administered via intravenous (IV) infusion on day 1 of each cycle and tazemetostat (800 mg) was given orally twice daily (BID) on days 1 to 21. Primary endpoints were safety and tolerability, and to identify a recommended phase II dose (RP2D) for atezolizumab. Secondary efficacy endpoints included response rate and duration of response. RESULTS: A total of 43 patients were enrolled, receiving a median of 3 prior lines of treatment (range: 1-9). The RP2D for atezolizumab was 1200 mg IV infusion every 3 weeks in combination with tazemetostat 800 mg BID. At the RP2D, adverse events reported in ≥20% patients were anemia(11 patients [26%]), fatigue (10 patients [23%]), and nausea (10 patients [23%]). Overall response rate was 16% (complete response rate: 7%). Median progression-free survival was 2 months (range: 0-24) and median overall survival was 13 months (range: 1-29). CONCLUSIONS: The combination of atezolizumab and tazemetostat was determined to be safe and tolerable. However, anti- tumor activity of the combination was modest.
|
Authors | Maria Lia Palomba, Guillaume Cartron, Leslie Popplewell, Vincent Ribrag, Jason Westin, Ling-Yuh Huw, Shefali Agarwal, Mahesh Shivhare, Wan-Jen Hong, Aparna Raval, Alice C Chang, Elicia Penuel, Franck Morschhauser |
Journal | Clinical lymphoma, myeloma & leukemia
(Clin Lymphoma Myeloma Leuk)
Vol. 22
Issue 7
Pg. 504-512
(07 2022)
ISSN: 2152-2669 [Electronic] United States |
PMID | 35151584
(Publication Type: Clinical Trial, Phase I, Journal Article, Research Support, Non-U.S. Gov't)
|
Copyright | Copyright © 2022 The Authors. Published by Elsevier Inc. All rights reserved. |
Chemical References |
- Antibodies, Monoclonal, Humanized
- B7-H1 Antigen
- Benzamides
- Biphenyl Compounds
- Morpholines
- Pyridones
- atezolizumab
- tazemetostat
|
Topics |
- Antibodies, Monoclonal, Humanized
- B7-H1 Antigen
- Benzamides
- Biphenyl Compounds
- Humans
- Lymphoma, Large B-Cell, Diffuse
(drug therapy, pathology)
- Lymphoma, Non-Hodgkin
(drug therapy)
- Morpholines
- Pyridones
- Tumor Microenvironment
|